Benchmark Reiterates Speculative Buy on Harvard Bioscience, Maintains $7 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on Harvard Bioscience (NASDAQ:HBIO) and maintains a $7 price target.
June 22, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on Harvard Bioscience and maintains a $7 price target.
The reiteration of the Speculative Buy rating and maintenance of the $7 price target by Benchmark analyst Bruce Jackson indicates a positive outlook for Harvard Bioscience's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100